Gastrografin

Selected form

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gastrografin

Quick Facts

Property	Description
Active Ingredient	Diatrizoate Meglumine and Diatrizoate Sodium
Form	Oral and Rectal Solution (Aqueous)
Pharmacological Class	Radiopaque Contrast Medium
General Purpose	Diagnostic imaging of the gastrointestinal tract
Origin	Synthetic

What Type of Medicine is Gastrografin?

Gastrografin is a specialized, synthetic radiopaque contrast medium used exclusively for medical imaging; it is not a therapeutic drug designed to treat diseases. This preparation is classified as an ionic iodinated contrast media. Its primary function is to enhance the visibility of internal structures during X-ray and computed tomography (CT) scans. Its formula, containing diatrizoate salts, is clinically recognized for its utility when a water-soluble agent is necessary, which is critical for non-invasive gastrointestinal imaging when perforation is suspected.

Composition and Form: The Aqueous Solution

Gastrografin is supplied as an oral and rectal solution—a water-soluble, liquid preparation intended for enteral administration to fill the digestive tract. The solution’s primary active ingredients are Diatrizoate Meglumine and Diatrizoate Sodium, which are salts of Diatrizoic Acid dissolved in an aqueous vehicle. A distinctive feature is that this vehicle is often palatably flavored, which aids patient compliance. The hypertonic nature of this combination product is a key characteristic that causes it to draw water into the bowel, ensuring effective visualization.

General Purpose: Visualizing the Gastrointestinal Tract

The overarching purpose of Gastrografin is purely diagnostic: to provide clear opacification and delineation of the gastrointestinal tract for radiological assessment. The solution’s high radiodensity enables the absorption of X-rays, which creates a sharp contrast between the filled internal organs (like the stomach and intestines) and the surrounding soft tissues. A typical use scenario involves visualizing the anatomy of the bowel, which helps doctors accurately identify and assess structural anomalies.

Regulatory References

NIH StatPearls: Intravenous Contrast

What side effects are possible with Gastrografin?

Possible Side Effects and Safety Information

Gastrografin (diatrizoate meglumine and diatrizoate sodium) is a water-soluble, iodinated contrast agent. As with any medication, it carries a risk of side effects, ranging from common and mild to rare and severe. Patients should be monitored following administration.

Common and Mild Side Effects

The most frequently reported adverse reactions are generally mild and temporary, and include gastrointestinal issues due to the hyperosmolarity of the solution:

Nausea
Vomiting
Diarrhea (usually ceases after the bowel empties)
Abdominal pain

Other common reactions may include headache, dizziness, and a feeling of warmth or flushing.

Serious Side Effects and Warnings

Allergic/Hypersensitivity Reactions

Serious, rarely fatal, hypersensitivity reactions (anaphylaxis) can occur, typically within minutes to hours, but sometimes delayed (up to several days). Symptoms may include:

Swelling of the face, lips, tongue, or throat (angioedema)
Difficulty breathing, wheezing, or shortness of breath
Severe rash, hives, or itching
Rapid heart rate or sudden drop in blood pressure (shock)

Dehydration Risk

Due to its high osmotic pressure, Gastrografin may draw a significant amount of fluid into the intestines, potentially leading to dehydration and electrolyte imbalance. Adequate hydration must be maintained, especially in infants, elderly, or severely debilitated patients.

Risk of Aspiration

If the solution is aspirated (inhaled) into the lungs, it can cause serious complications such as chemical pneumonia, pulmonary edema, or respiratory distress. This risk is particularly high in patients with a history of aspiration or known broncho-oesophageal fistula.

Contraindications

Gastrografin should not be administered to patients with a known history of hypersensitivity to any of its components. Caution is advised for patients with a history of asthma, allergies, or an overactive thyroid gland (hyperthyroidism), as the iodine content may affect thyroid function.

Overdose and Emergency Response

Overdose and When to Seek Help

Because Gastrografin is typically administered in a controlled medical setting by a healthcare professional, accidental overdose is unlikely. However, if a significantly excessive dose is administered, the primary concerns relate to its high osmotic pressure, which can draw substantial fluid into the bowel. In vulnerable patients, such as those who are elderly, debilitated, or severely dehydrated, this fluid shift can lead to serious consequences like hypovolemia (decreased blood volume), severe dehydration, hypotension (low blood pressure), and even a shock-like state.

Overdose-related symptoms are primarily managed with supportive care, focusing on correcting fluid and electrolyte imbalances.

Immediately seek emergency medical attention if you or the patient experience any of the following severe signs, which may indicate a life-threatening reaction or complication:

System	Symptoms Indicating Emergency Care
Allergic/Hypersensitivity	Signs of anaphylaxis, including difficulty breathing, swelling of the face, lips, or tongue, severe hives, or loss of consciousness.
Cardiovascular	Chest pain, very fast or irregular heartbeat (tachycardia), or signs of shock (e.g., severe dizziness, passing out, or extremely low blood pressure).
Respiratory	Acute shortness of breath, wheezing, or coughing, which could indicate aspiration or pulmonary edema.

Contact the administering physician or go to the nearest emergency department immediately if any serious or unexpected side effects occur.

Therapeutic Uses of Gastrografin

Gastrografin (Diatrizoate Meglumine and Diatrizoate Sodium Solution) is generally used as a radiopaque contrast medium for the radiological examination of the gastrointestinal tract. It is commonly used in clinical settings that involve acute or unstable symptom patterns where a non-water-soluble agent, such as barium sulfate, may not be feasible or may be potentially dangerous.

The preparation is applied in addressing a wide range of indications associated with symptoms linked to organ-specific functional stress, including suspected perforation of the esophagus or gastrointestinal tract, suspected partial or complete stenosis, and the visualization of a gastrointestinal fistula. The use of this water-soluble contrast medium provides supportive relief when symptoms interfere with routine activities. It is relevant when supportive symptom management is appropriate. Furthermore, the contrast medium is commonly used to help with the non-operative treatment of uncomplicated meconium ileus in infants, a specific therapeutic application that may assist with easing the overall symptom load. This application is considered relevant in contexts involving heightened systemic burden.

Quick Fact: Supportive management for symptoms that create noticeable physiological strain

Eligibility and Restrictions for Use

Who Can and Cannot Use Gastrografin?

This eligibility profile is based strictly on information documented in authoritative government regulatory sources.

Absolute Contraindications

Gastrografin must not be used by populations with the following conditions:

Hypersensitivity: Known allergy or sensitivity to the active ingredients (diatrizoate meglumine, diatrizoate sodium) or to any other component, including iodine or iodine-containing contrast media.
Thyroid Dysfunction: Patients with manifest hyperthyroidism (overt hyperthyroidism).
Aspiration Risk: Undiluted administration is contraindicated if there is a suspected possibility of aspiration or an abnormal connection to the airways (broncho-oesophageal fistula).

Restricted and Conditional Use

Use is subject to special warnings and precautions in several groups:

Population/Condition	Restriction/Requirement
Pediatric Use (Newborns, Infants, Children)	Must not be administered undiluted due to low plasma volume and risk of serious hypovolemia.
Dehydration/Low Plasma Volume	Undiluted use is contraindicated. Fluid and electrolyte imbalance must be corrected before use.
Allergic History	Patients with a history of bronchial asthma or previous allergic disorders require particularly careful risk assessment.
Pregnancy and Lactation	Safety is not established; adequate studies have not been conducted.

Use is generally permitted for adults and older children unless specific contraindications or risk factors are present.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Gastrografin (Diatrizoate Meglumine and Diatrizoate Sodium Solution) is primarily defined by the properties of iodinated contrast media and its potential to interfere with diagnostic procedures or exacerbate medication-related risks.

Clinically Relevant Interactions

Interacting Substance/Class	Regulatory Finding	Practical Implication
Radioisotopes (e.g., I-131)	Iodine content reduces the thyroid's capacity to take up radioisotopes.	Requires timing separation; thyroid tests may be inaccurate for up to two weeks or longer after administration.
Beta-blockers	Can aggravate the severity of hypersensitivity or anaphylactoid events to contrast media.	Use with caution; patient assessment is necessary prior to administration.
Interleukin (IL-2)	Increases the reported prevalence of delayed reactions (e.g., fever, rash) to contrast media.	Increased monitoring for delayed adverse events is warranted.
Metformin	Iodinated contrast media can potentially cause changes in renal function, which is a risk factor for lactic acidosis in patients taking Metformin.	Requires a risk management protocol, particularly in patients with pre-existing renal impairment.
Barium Sulfate Preparations	If used concurrently, all warnings and precautions relevant to the barium sulfate product must also be observed.	Concurrent use requires adherence to the safety profile of the barium product.

Food and Pharmacokinetic Interactions

Food and Alcohol: No specific direct drug-food or drug-alcohol interactions are formally documented in regulatory labeling; however, the hyperosmolar nature of Gastrografin may lead to fluid shifts and diarrhea, potentially impacting the absorption of other oral medications or affecting hydration status.

Metabolism: Due to minimal systemic absorption of the active component (Diatrizoate), interactions mediated through hepatic cytochrome P450 (CYP) enzymes or common drug transporters are generally not applicable for the oral/rectal use of this product.

Mechanism of Action

Gastrografin's function relies on two primary physicochemical mechanisms rather than pharmacological receptor engagement. The molecule contains heavy iodine atoms which serve as the main biological target for X-ray photons; this physical attenuation creates high radiopacity, resulting in the physiological effect of visibly outlining the internal anatomy of the gastrointestinal (GI) tract during imaging. The agent exhibits minimal systemic pharmacological activity and is not significantly absorbed or metabolized by the body's primary enzyme systems. The second mechanism involves Gastrointestinal Fluid Dynamics. A high concentration of the contrast salts establishes a strong osmotic gradient in the GI lumen, compelling water and electrolytes to shift from the surrounding tissue into the intestine. This process increases intraluminal volume, leading to mechanical distension and stimulation of peristalsis, thereby accelerating luminal transit. The overall mechanistic effect is localized and transient.

Dosage and Administration Information

Gastrografin is a high-osmolar, water-soluble radiopaque contrast medium used for diagnostic imaging of the gastrointestinal (GI) tract. It is administered strictly by oral (by mouth or tube) or rectal (as an enema or enterostomy instillation) routes; it must not be used intravascularly.

Administration and Dosage Rules

Administration scope	Rule/Dosage
Route of administration	Oral or Rectal only. Not for intravenous use.
Adult Oral Dose	60 mL for stomach visualization; maximum of 100 mL for GI tract follow-through.
Pediatric Oral Dose	Children up to 10 years: 15–30 mL is generally sufficient. Infants/Young Children: 15–30 mL is recommended.
Adult CT Body Imaging Dose	240 mL of a dilute solution (e.g., 25-77 mL diluted to one liter with tap water), administered 15 to 30 minutes prior to imaging.
Rectal Enema Dose	Up to 500 mL of a dilute solution. Dilution with 3–5 times its volume of water is required, depending on patient age.

Preparation and Procedural Steps

Preparation requirements include mandatory dilution for specific patient groups and procedures to manage the hyperosmolarity of the solution. For elderly or severely debilitated (cachectic) patients, the oral dose should be diluted with an equal volume of water. For children, infants, and newborns, greater dilution (e.g., 1 part contrast to 3 parts water) is advised for oral use, and pre- and post-administration hydration must be assured, correcting any existing electrolyte imbalances.

Procedural steps require that the diagnostic procedure be performed under the direction of appropriately trained personnel. Any unused contrast medium solution must be discarded within 72 hours after the bottle is opened.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Gastrografin

Evidence for Diagnosing Bowel Obstruction and Perforation

Research has examined the use of Gastrografin in detecting issues in the bowel, particularly conditions associated with acute or disruptive episodes, such as blockages or tears. These issues fall under outcomes related to systemic or functional imbalance. Studies have focused on how well the substance appears on X-rays or CT scans, which is relevant in evidence describing how symptoms are measured.

The body of research includes both observational studies, where patient patterns were monitored, and some trials. Research explored the patterns of how quickly the substance moves through the digestive system, and these findings help contextualize whether the blockage resolved without surgery in the observed populations. Specifically, studies report how symptoms changed in the observed populations and findings describe patterns related to diagnostic accuracy for identifying perforations.

Evidence for Managing Adhesional Small Bowel Obstruction (SBO)

Gastrografin was studied for its role in managing a small bowel obstruction caused by adhesions, which are scar tissues that form after previous abdominal surgery. This condition is characterized by fluctuating or episodic manifestations and is often monitored through outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level.

Studies, including some randomized trials, explored whether administering Gastrografin was studied for its association with whether the obstruction resolved, and whether surgery was needed. The findings describe patterns observed in the studies regarding the rate at which the blockage resolved on its own after the substance was given. These studies contribute to understanding symptom patterns in patients experiencing temporary physiological imbalance.

What is Still Uncertain About Gastrografin

While studies contribute to the broader evidence landscape, there are several areas where research is still needed. The overall evidence is limited for special populations such as children and people with comorbid conditions.

For instance, the findings were mixed in some studies that explored its use in follow-up care. The sample sizes were modest in some of the most relevant trials, meaning that while findings help describe patterns, they are not based on the largest possible patient pools. Evidence highlights what is known — and what is still uncertain — and research does not determine whether an individual will respond similarly to the patterns observed in group studies.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Gastrografin (FAQ)

Q: What is Gastrografin used for?

A: Gastrografin (Diatrizoate Meglumine and Diatrizoate Sodium Solution) is a contrast agent used in diagnostic procedures. It is primarily administered for visualization of the gastrointestinal tract in certain X-ray studies, such as examining the esophagus, stomach, and intestines. It may also be used as an aid in computed tomography (CT) imaging of the abdomen.

Q: How does Gastrografin work in the body?

A: Gastrografin contains iodine, which absorbs X-rays. When administered orally or rectally, the contrast agent coats the lining of the digestive tract, making the structure visible on X-ray images. This allows healthcare professionals to observe the shape and function of these organs.

Q: Who should not take Gastrografin?

A: Patients with known hypersensitivity to diatrizoate salts or other iodine-containing contrast media should generally not receive Gastrografin. It is important to discuss your full medical history with your healthcare provider, particularly if you have a history of thyroid disease, asthma, severe kidney impairment, or multiple myeloma.

Q: What are the common side effects of Gastrografin?

A: The most frequently reported adverse effects associated with Gastrografin include temporary nausea, vomiting, or diarrhea. In some individuals, mild abdominal cramping may occur. Less commonly, patients may experience an allergic reaction, which can range from mild skin symptoms to more serious reactions.

Q: Can Gastrografin be used during pregnancy or while breastfeeding?

A: The use of Gastrografin during pregnancy or while breastfeeding should be carefully considered by a healthcare provider. Only a physician can weigh the potential benefits against any potential risks to the fetus or infant. It is essential to inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding before receiving this contrast agent.

How should Gastrografin be stored and disposed of?

Official Storage and Handling Requirements

Gastrografin must be stored strictly mathbfbelow 25, C. To maintain product integrity, it is mandatory to keep the medicine in the original container to protect it from mathbflight and mathbfX -rays.

If the temperature drops mathbfbelow 7, C and mathbfcrystallization occurs, the solution's original state can be restored by mathbfgently warming and shaking the bottle. Before administration, the solution must be mathbfvisually inspected to ensure it is clear and free from particles.

Stability and Disposal

Once the bottle has been mathbfopened, any unused portion of the solution must be mathbfdiscarded within 24 to 72 hours, depending on the specific product labeling. The product must be stored mathbfout of the sight and reach of children. Disposal of mathbfunused medicine or waste material should strictly follow mathbflocal regulatory requirements; do mathbfnot dispose of it via household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

USA

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z